Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

Pascal Hammel, Carole Vitellius, Émeric Boisteau, Mathilde Wisniewski, Elise Colle, Marc Hilmi, Christelle Dengremont, Sandra Granier, Anthony Turpin, Louis de Mestier and Cindy Neuzillet

Abstract: Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIROX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting.

Keywords: chemotherapy, FOLFIROX, gemcitabine, maintenance, nab-paclitaxel, olaparib, pancreatic cancer, PARP, quality of life, toxicity

Received: 17 February 2020; revised manuscript accepted: 5 June 2020.

Introduction
Pancreatic ductal adenocarcinoma (PDAC) will become the second cause of cancer mortality in developed countries in the next few years.1,2 Gemcitabine was the first available drug with modest efficacy in advanced PDAC.3 After almost 15 years of failure to improve efficacy by combining this agent with other drugs, significant breakthroughs were made between 2011 and 2013 using more efficient but also more toxic chemotheraphy regimens. Combinations of 5-fluorouracil (5-FU) and folinic acid, irinotecan, and oxaliplat-in (FOLFIRINOX), and then gemcitabine (Gem) plus nab-paclitaxel (NabP) were found to be superior to gemcitabine in large phase III randomized trials.4,5 Cisplatin–gemcitabine–capecitabine–epirubicin/docetaxel regimens (PEG, PEGF4, PEXG20, PAXG) were also developed by Reni et al.4,5,9 Since these results were published, a significant subset of patients with metastatic PDAC have achieved tumor control of more than 6 months, resulting in a paradigm shift. Indeed, the race to administer treatment lines with limited and short-term efficacy (i.e. gemcitabine or 5FU/platinum based) is no longer the ultimate goal. Instead the previously unimaginable objective of obtaining relief from chemotherapy and limiting therapeutic toxicity while still maintaining both tumor control and patient quality of life (QoL) has now become a focus of research (Figure 1).

Concept of maintenance in PDAC with cytotoxic agents
Maintenance strategies had been developed in patients with tumors that are more chemosensitive than PDAC, such as in colorectal or lung cancers. These results have shown that continuing uninterrupted full-dose chemotherapy until progression...
Figure 1. Concept of maintenance therapy compared with the usual schemas of chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC): after sustained tumor control has been obtained, lightened chemotherapy is continued while the neurotoxic drug [nab-paclitaxel (NabP) or oxaliplatin] is stopped, or another drug is proposed (e.g. olaparib for patients with gBRCAm). At progression, reintroduction of first-line drugs can be proposed depending on the patient’s general status and remaining neurotoxicity. Prog, tumor progression; BSC, best supportive care.

Table 1 summarizes the studies on maintenance in PDAC patients.

Maintenance after FOLFIRINOX induction: results of the PANOPTIMOX study
The first option was tested following induction chemotherapy with FOLFIRINOX and Gem–NabP combinations, which were established as first-line standards. Median progression-free survival (PFS) in the pivotal study with FOLFIRINOX (PRODIGE4/ACCORD 11) was 6.4 months. This duration of oxaliplatin treatment is associated with a high risk of permanent cumulative sensitive neuropathy, as observed in colorectal cancer. Indeed, grade 3 or higher neuropathy was reported in 17% of patients.4 A similar rate of neuropathy was also observed with NabP (17%) in the study by von Hoff et al.5

Oxaliplatin neurotoxicity including cold-induced paresthesia or dysesthesia of the distal extremities usually resolves within a week following the first cycles (grade 1).18 Chronic neuropathy develops with cumulative doses >540–600 mg/m².19 In the treatment of PDAC with FOLFIRINOX, this represents about six cycles/3 months of oxaliplatin at the recommended dosage of 85 mg/m². Otherwise, neuropathy often limits taxanes’ administration after 5–6 months of therapy (cumulative doses >1400 mg/m² with paclitaxel).20

Retrospective series have reported a median PFS (including reintroduction of induction chemotherapy) and overall survival (OS) of 10–14 months and 17–18 months, respectively, with
Table 1. Main publications of maintenance therapies in patients with PDAC.

| Study          | Study type | Maintenance treatment | Induction chemotherapy | Population (n patients) | Results                                                                 |
|----------------|------------|-----------------------|------------------------|-------------------------|--------------------------------------------------------------------------|
| Reure et al.   | Retrospective | Capecitabine          | After 4–8 cycles of FOLFIRINOX | 30                      | OS: 17 months. Survival rates: 73% at 1 year (95% CI 0.59–0.91) and 25% at 2 years (95% CI 0.13–0.50). PFS1: 5months–PFS2: 10 months |
| Dahan et al.   | Phase II PANOPTIMOX | FOLFIRINOX continuous (A) versus LV5FU2 maintenance (B) versus Gem–irinotecan (C) After FOLFIRINOX | 273                    | 6-month PFS: 47% [A], 44% [B], 34% [C]—4-months RR: 35% [A], 41% [B], 17% [C] PFS: 6.3 months [A], 5.7 months [B], 4.5 months [C] OS: 10.1 months [A], 11.2 months [B], 7.3 months [C] Duration maintenance (B): 3.3 months (0.003–22.6) |
| Reni et al.    | Phase II PACT 12 | Observation (A) versus sunitinib (B) 37.5mg/day After various chemotherapies combination (mainly Gem/platinum based) | 56                     | A versus B: 6-month PFS: 3.6% (95% CI 0–10.6%) versus 22.2% (95% CI 6.2–38.2%); p < 0.01; 2 years OS: 7.1% (95% CI 0–16.8%) versus 22.9% (95% CI 5.8–40.0%); p = 0.11, Stable disease: 21.4% versus 51.9% (p = 0.02). |
| Petrioli et al.| Observational | Gem                    | After three cycles of Gem-NabP | 37 (>70 years)         | 6-month DCR: 61% (95% CI 45–77) PFS: 6.4 months (95% CI 5.4–8.3) OS: 13.4 months (95% CI 11.1–16.7). |
| Relias et al.  | Retrospective OPTINAB | Gem                    | After Gem-NabP when neuropathy occurred | 27                      | Gem maintenance in seven patients with grade 3 neuropathy (median delay: 4.2 months) Mean duration maintenance: 2.8 months. Reintroduction NabP in 6/7 patients. PFS2: 2.2 months (range 1–4 months). DDR: 8.2 months (8–13) and 9.4 months with reintroduction of NabP OS: 11.7 months |
| Zhang et al.   | Phase II | S1                     | After six cycles of NabP plus S1 | 32                      | ORR (primary objective): 53.1% Disease control rate: 87.5% PFS: 6.2 months OS: 13.6 months |
| Golan et al.   | Phase III | Olaparib versus placebo | After platinum-based chemotherapy | 154 (gBRCA1/2 mutation) | PFS: 7.4 months versus 3.8 months (HR 0.53; 95% CI 0.35–0.82; p = 0.004—OS: 18.9 months versus 18.1 months (HR 0.91; 95% CI 0.56–1.46; p = 0.68 Anemia [11%], fatigue [5%], decrease appetite [3%], abdominal pain [2%], vomiting [1%], arthralgia [1%] (with olaparib) |

DCR, disease control rate; DDR, duration of disease control; Gem, gemcitabine; NabP, nab-paclitaxel; ORR, objective response rate; OS, overall survival.

oxaliplatin/irinotecan stop-and-go strategies after FOLFIRINOX induction chemotherapies in advanced PDAC.11 The prospective phase II PRODIGE 35-PANOPTIMOX trial by Dahan et al.12 has assessed three arms: (i) 12 cycles of FOLFIRINOX full-dose (arm A); (ii) 8 cycles of FOLFIRINOX and then maintenance using 5-FU plus leucovorin (LV5FU2) (arm B) with FOLFIRINOX reintroduction at progression; and (iii) a sequential strategy alternating Gem and the 5-FU–irinotecan combination (FOLFIRI-3) (FIRGEM) (arm C). With the 6-month PFS rate as the main objective of the study, similar results were obtained in arms A and B (47% and 44%, respectively), with only 34% in arm C. Median OS was also not impaired with
Therapeutic Advances in Medical Oncology 12

Maintenance therapy: 10.1 months and 11.2 months in arms A and B, respectively, and 7.3 months in arm C. It is important to note that the severe neurotoxicity rate was higher in the maintenance arm (B) probably because of a higher cumulative oxaliplatin dose following reintroduction in this study arm. Indeed, the severe neurotoxicity rate was similar in the two groups with 6-month chemotherapy regimens. The difference was found after this period with more neurotoxicity in arm B than in arm A. Although this was a non-comparative study, these results provide the first prospective evidence of continuation maintenance therapy with LV5FU2 in metastatic PDAC after FOLFIRINOX induction therapy. The full paper, including analysis of QoL and predictive factors of maintenance efficacy is pending. Some clinicians favor a pragmatic approach, with slower tapering of FOLFIRINOX doses, including a step using FOLFIRI for a few cycles before administering LV5FU2. However, more robust evidence of this FOLFIRI maintenance step is needed.

Maintenance in PDAC using targeted agents with angiogenesis inhibitors

In the prospective phase II study PACT-12 by Reni et al., the authors tested the Folkman’s induced dormancy theory, that is hypothesizing that blocking angiogenesis would prevent tumor progression and maintain stable disease. The biological rationale of this approach is that tumor cell proliferation is balanced by a high rate of apoptosis when angiogenesis is blocked. In this trial, 56 patients with controlled metastatic PDAC after 6 months of chemotherapy were randomized into observation or 37.5 mg of sunitinib daily continuously until progression. As reported previously, sunitinib toxicities included thrombocytopenia (12%), neutropenia (12%), hand–foot syndrome (12%) and diarrhea (8%). PFS at 6 months was 3.6% versus 22.2%, \( p < 0.01 \), 2-year OS was 7.1% versus 22.9% \( p = 0.11 \), and disease control was 21.4% versus 51.9% \( p = 0.02 \) in the observation and sunitinib arms, respectively. This study confirmed that targeting the VEGFR pathway, whose relevance has been shown to be limited in bulky and rapidly growing disease, could be valuable in maintaining tumor control once tumor growth has been slowed and optimal cytoreduction has been obtained.

Maintenance after Gem–NabP induction

A prospective observational study with Gem–NabP by Petrioli et al. treated 36 older patients in good condition (PS 0–1), median age 77 years old (71–86), with metastatic (78%) or locally advanced (22%) PDAC. Three cycles of Gem–NabP were administered with a dose reduction in vulnerable patients or patients older than 80. Patients without progressive disease then received gemcitabine single agent 1000 mg/m² weekly for 3 or 4 weeks as maintenance therapy until disease progression or unacceptable toxicity. After induction treatment with Gem–NabP, a partial response, stable disease, or progressive disease was observed in 18 (50%), 13 (36%), and 5 patients (14%), respectively. Overall, 31 patients (86%) received a median of 3 (2–9) cycles of gemcitabine maintenance therapy. The 6-month disease control rate (main objective of study) was 61% (95% CI 45–77). Median PFS was 6.4 months and median OS was 13.4 months. These results were comparable with those of the pivotal trial (6.7 months and 8.5 months, respectively). During the maintenance period, grade 3 hematological toxicity only occurred in six patients (19%). Grade 2 neuropathy, which affected 17% of patients during Gem–NabP induction did not worsen during gemcitabine maintenance.

In a retrospective study by Relias et al. a “stop-and-go” strategy (OPTINAB) included the reintroduction of NabP after neurotoxicity had resolved. NabP was suspended if grade 3 neuropathy occurred and then only reintroduced if biochemical or imaging progression developed. In this series of 27 treated patients, 7 (25%) developed a grade 3 peripheral neuropathy after a mean 4.2 months (2–4) and gemcitabine alone was continued for a mean 2.8 months. Neuropathy improved and regressed to grade 1 or less after 29 days. After NabP was reintroduced at tumor progression, tolerance was acceptable in all patients except one in whom neuropathy rapidly worsened and NabP was stopped. These six patients continued NabP with a mean second PFS of 2.2 months (1–4). Disease control in this sub-group of patients lasted a mean 9.4 months and average OS was 11.7 months.

Zhang et al. tested a first-line treatment of advanced PDAC with a NabP and S-1 combination followed by S-1 maintenance therapy. In this phase II study, 120 mg/m² of NabP was administered on days 1 and 8, and 80–120 mg/day of S-1 depending on body surface area, twice a day on days 1–14 every 3 weeks. Patients with controlled tumors (stable disease + partial or complete response) after six cycles then received the same schedule of S-1 maintenance therapy until disease...
progression or unacceptable toxicity. The objective response rate (primary objective) in the intention-to-treat population of 32 patients was 53.1%, and the disease control rate was 87.5%. Median PFS and OS were 6.2 months and 13.6 months, respectively. Toxicity was mainly hematologic (grade 3/4 neutropenia: 27.6%).

**Maintenance in PDAC with cytotoxic agents: lessons, next steps**

Overall, the above-mentioned studies show that maintenance therapy by tapering of initially effective induction chemotherapy is feasible with acceptable toxicity. In addition, OS was not decreased with LV5FU2 maintenance following a limited period of FOLFIRINOX induction therapy compared with standard treatment,12 or with Gem maintenance following limited Gem–NabP induction compared with pivotal trials.14,15 Moreover, survival with S-1 maintenance therapy following S-1–NabP induction therapy was promising.16 While these strategies could be directly applicable further comparisons of their efficacy, toxicity, and QoL are needed to those of standard treatment especially for NabP-based regimens. Another potential interest of early oxaliplatin or NabP interruption before reaching severe neurotoxicity is to allow reintroduction of these drugs when tumor progression occurs during maintenance therapy. However, the most appropriate strategy at progression remains to be defined: rechallenge or switch? Finally, biomarkers are needed to help determine the treatment strategy, possibly including those related to the type, duration, and extent of initial response.

More than 25% of patients with PDAC are old and/or frail thus not eligible for combination chemotherapies, and only Gem can be given.21,22 A subset of these patients may achieve an appreciable and sustained tumor control with acceptable toxicity. Therapeutic breaks, or maintenance with reduced dosage of Gem or other drugs in the future may be envisaged. In these patients, supportive care remains of course a priority.

**Maintenance in PDAC with targeted agents: the example of PARP inhibitors**

**BRCAAness mutations in PDAC**

Targeting of biological abnormalities is needed to identify new maintenance therapies in PDAC patients. However, targeted therapies, alone or combined with gemcitabine, have failed to improve clinical outcomes in patients with progressive PDAC. An unstable genotype with numerous structural variations is present in about 10–15% of PDAC.23,24 This genomic instability co-segregates with inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) or a mutational signature of DNA damage repair deficiency. A germline mutation in BRCA genes (gBRCAm) is identifiable in about 5–7% patients with PDAC and somatic mutations in genes involved in DNA repair such as BRCA2, BRCA1, PALB2, ATM, and RAD51 may also be identified. Recently, the prevalence of homologous recombination (HR) DNA damage repair deficiencies was re-evaluated, showing an enlarged spectrum of double-strand break (DSB) repair deficient genes called “BRCAAness” signature genes, which affect up to 17.4% of PDAC.23–28

The presence of DSB repair or mismatch repair in these canonical HR genes leads to activation of CD8-positive T-cell lymphocytes or overexpression of regulatory molecules such as cytotoxic T-cell lymphocyte antigen 4 or programmed cell death 1, due to the high frequency of somatic mutations and the burden of tumor-specific neoantigens, at a lesser degree than microsatellite unstable tumors.23 PARP repairs single-strand DNA breaks through the base excision repair pathway and PARPi act by catalytic inhibition of the PARP1 protein.29 Single-strand DNA breaks remain when PARP function is altered, then irreparable DSB occur during replication in tumor cells lacking HR proteins, leading to cell death through synthetic lethality principle.27

**PDAC and germinal BRCA mutations: the example of olaparib**

The potential efficacy of olaparib as a single agent in patients with gBRCAm and PDAC, even with pre-treatment, was suggested by the results of a phase II trial by Kaufman et al.30 The response rate, median PFS and OS were 21.7%, 4.6 months and 9.8 months, respectively. The efficacy of olaparib was prospectively assessed in the phase III POLO study. A total of 3315 patients with PDAC were screened in 10 countries in this study and 154 gBRCAm patients with controlled tumors after receiving platinum-based induction chemotherapy, mainly FOLFIRINOX, for ≥16 weeks (one third received >6 months induction chemotherapy) were randomized: 92 to receive olaparib and 62, a placebo,17,31 PFS, the primary endpoint of the study, was significantly longer in the
olaparib arm than in the placebo arm (median 7.4 months versus 3.8 months, respectively; HR 0.53; 95% CI 0.35–0.82; \( p = 0.004 \)).\(^{17} \) The rate of grade \( \geq 3 \) adverse events, mainly anemia and fatigue, was 39.6% in the olaparib group and 23.3% in the placebo arm, and 5.5% and 1.7% of patients, respectively, discontinued treatment due to an adverse event. The QoL was not impaired in patients receiving olaparib compared with those with placebo, which is an important goal for any maintenance therapy.\(^{32} \) Although there was no difference in OS between the olaparib and placebo arms in the first study by Golan\ et \ al.\(^{17} \) those results were based on an interim analysis at 46% maturity and the role of the reintroduction of effective chemotherapies or even olaparib, even though cross-over was not allowed, may have biased the OS results. It is important to note that the median sustained response in the subgroup of 18 patients receiving olaparib (23.1%) who achieved a tumor response was significant (24 months versus 3.7 months in the placebo arm). In addition, the longer secondary PFS (median, 13.2 months versus 9.2 months, respectively; HR 0.76; 95% CI 0.46–1.23; \( p = 0.26 \)) suggests that there was a sustained benefit with post-protocol chemotherapies following olaparib.\(^{17} \)

**PDAC and BRCA mutation: other PARP inhibitors and remaining questions**

There are several steps needed to confirm the effectiveness of maintenance therapies. First, it must be determined whether patients with PDAC that harbor DNA damage response and repair germline mutations other than BRCA 1/2, or sporadic PDAC and somatic BRCA/BRACness mutations, are sensitive to PARPi. In addition, resistances to PARPi caused by primary or secondary mutations in the BRCA genes, in example by restoring the function of HR repair genes and those in the DNA-binding domains of PARP1 or by amplification of the mutation-carrying BRCA2 allele with increased RAD51 loading and PARPi resistance, must be better understood.\(^{33,34} \) The characteristics of tumors in gBRCAm patients (~30%) with rapid progression under olaparib must also be better defined to propose the optimal therapeutic management. Moreover, studies are needed to determine whether olaparib and other PARPi should be used in settings other than metastatic PDAC (adjuvant treatment, etc.) and whether combining PARPi with other drugs, such as platinum salts or checkpoint inhibitors could improve tumor control considering the previously described immunological characteristics of these tumors.\(^{33} \) O’Reilly\ et \ al.\(^{35} \) recently reported the results of a randomized phase II trial in 56 patients showing that the cisplatin–Gem combination was an effective regimen in patients with advanced PDAC (metastatic: 84%) with the germinal BRCA 1/2 (94%) or PALB2 (6%) mutations. However, concurrent administration of veliparib did not improve the response rate (74.1% versus 65.2%, \( p = 0.55 \)) or the disease control rate, PFS, or OS (100% versus 78.2%, \( p = 0.02 \); 10.1 months versus 9.7 months, \( p = 0.73 \); 15.5 months versus 16.4 months, \( p = 0.6 \), respectively). Nevertheless, no conclusion can be drawn on the potential efficacy of veliparib in a maintenance setting because the drug was administered as induction therapy without a previous selection for good PARPi candidates (platinum responders). Moreover, whether the efficacy of veliparib differs from other PARPi in that setting remains to be defined. On the other hand, rucaparib appears to be a promising maintenance therapy in platinum-sensitive PDAC patients with germline gBRCA/PALB2 mutations.\(^{36} \)

At present, the patient population eligible for olaparib maintenance therapy is small due to the low rate of gBRCAm patients with metastatic PDAC who are fit to receive platinum-based chemotherapy and without tumor progression during this induction treatment. Moreover, access to rapid genetic screening is still an important issue.

**Future options for maintenance therapy, role of immunotherapy**

Other drugs being currently tested for maintenance therapy include nimotuzumab (anti-EGFR), fluzoparib (PARPi), pembrolizumab (anti-PD-1), paricalcitol (analogue vitamin D), durvalumab (anti-PD-L1), vaccines (CV301, OSE-21), and nivolumab (anti-PD-1) (see Table 2).

The lack of efficacy of immunotherapies is mainly due to the low immunogenicity and non-inflamed phenotype of PDAC tumors. The abundant stroma generates a hypoxic microenvironment and drives the recruitment of immunosuppressive cells through cancer-associated fibroblast activation and transforming growth factor \( \beta \) secretion.\(^{37} \) The aim of the therapeutic strategy is to combine checkpoint inhibitors with other drugs, such as vaccines, oncolytic viruses, MEK inhibitors, cytokine inhibitors, and hypoxia- and stroma-targeting agents to increase immunogenicity as well as to recruit and activate effector T cells.
Otherwise, neoadjuvant strategies can favorably remodel the PDAC microenvironment by depleting regulatory T- and myeloid-derived tumor cells and decreasing stroma activation. In a series by Murakami et al., 84 patients with borderline/resectable PDAC received either neoadjuvant treatment with chemoradiotherapy before surgical resection or frontline resection. Analysis of resected specimens showed that the damage-induced molecular patterns of neoadjuvant treatment could favorably influence PDAC immunomodulation.

Two prospective trials are ongoing in France to test various maintenance strategies in metastatic PDAC. The TEDOPaM-PRODIGE 63 phase II study is evaluating maintenance therapy in patients with locally advanced or metastatic PDAC that has been controlled with eight cycles of FOLFIRINOX, using a polyantigenic HLA2-restricted vaccine OSE2101, alone or combined with nivolumab, with the reintroduction of FOLFIRI at progression, versus the continuation of FOLFIRI (Table 2). The MAZEPPA randomized phase II study is evaluating maintenance therapy with olaparib or selumetinib (MEK 1/2 inhibitor) plus durvalumab (anti-PDL-1) according to BRCAness and KRAS somatic status in patients with tumors controlled by FOLFIRINOX induction chemotherapy. One alternative to maintenance therapy is sequential treatment with Nal-IRI plus 5-FU/folinic acid for 2 months, then Gem–NabP for 2 months.

In the near future, in addition to clinical follow-up, imaging assessment and measurement of conventional serum tumor markers such as CA 19.9, the monitoring of circulating tumor DNA, tumor cells or extra-cellular vesicles will help guide maintenance therapies in patients with PDAC. This confirms the importance of carefully designing ancillary studies as well as those for treatment.

Conclusion
Owing to the availability of more effective first-line chemotherapy combinations, a significant subset of patients with metastatic PDAC may be candidates for maintenance therapies. While continuing with lower doses of chemotherapy is one strategy, administration of different drugs will also be a future option. In the small population of patients with gBRCAm PDAC, the POLO study paved the way for targeted maintenance therapy. These results can stimulate further studies and the design of innovative maintenance therapy trials, based on targetable biological abnormalities whenever possible, to maintain both QoL and increase OS.

Acknowledgement
The authors are grateful to Mrs Dale Roche-Lebrec for editing of the manuscript.

Table 2. Active trials of maintenance therapy in metastatic pancreatic cancer.

| Drug                | Target                          | Induction chemo | Maintenance schema                      | Phase | ClinicalTrials.gov identifier |
|---------------------|--------------------------------|-----------------|-----------------------------------------|-------|-------------------------------|
| Nimotuzumab         | EGFR                           | G + nimotuzumab + S1 | Nimo + S1 versus placebo + S1          | IV    | NCT02945267                   |
| Fluzoparib          | PARP1/2                        | FOLFIRINOX + Fluzoparib | Fluzoparib                             | Ib–II | NCT04228601                   |
| Pembrolizumab       | Anti-PD1, Analog of 1,25-dihydroxyergocalciferol | Pembrolizumab with paricalcitol or placebo | Pembrolizumab with paricalcitol or placebo | II    | NCT03331562                   |
| Paricalcitol        | PARP (germline or somatic BRCA1/2 or PALB2 mutation) | Platinum-based chemo | Rucaparib                               | II    | NCT03140670                   |
| Durvalumab          | PDL-1, CEA-MUC-1-TRICOM vaccine | MVA-BN-CV301 [prime] FPV-CV301 [boost] Durvalumab-capecitabine | Pembrolizumab with paricalcitol or placebo | I/II  | NCT03376659                   |
| OSE-21 vaccine      | Vaccine                         | FOLFIRINOX      | OSE-21 vaccine alone or with nivolumab, or FOLFIRI | II    | NCT03806309                   |

P Hammel, C Vitellius et al.
Conflict of interest statement
Pascal Hammel and Cindy Neuzillet: AstraZeneca, BMS, Celgene and OSE Immunotherapeutics. The other authors declare no conflict of interest relevant to this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Anthony Turpin https://orcid.org/0000-0002-2282-0101

References
1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2019; 74: 2913–2921.
2. Rawla P, Sunkara T and Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risks factors. World J Oncol 2019; 10: 10–27.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
6. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 2005; 6: 369–376.
7. Reni M, Cereda S, Rognone A, et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capectabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 2012; 69: 115–123.
8. Reni M, Zanon S, Peretti U, et al. Nab-paclitaxel plus gemcitabine, with or without capectabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomized phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3: 691–697.
9. Socinski MA, Scell MJ, Peterman A, et al. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second-line therapy in advanced stage IIIB/IV nonsmall cell lung cancer. J Clin Oncol 2002; 20: 1335–1343.
10. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop and go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 2006; 24: 394–400.
11. Reure J, Follana P, Gal J, et al. Effectiveness and tolerability of maintenance capectabine administered to patients with metastatic pancreatic cancer treated with first-line FOLFIRINOX. Oncology 2016; 90: 261–266.
12. Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol 2018; 36(Suppl.): abstract 4000.
13. Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer 2013; 49: 3609–3615.
14. Petrioli R, Torre P, Pesola G, et al. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol 2020; 11: 647–651.
15. Relias V, Maloney A, Smith MH, et al. Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine? Cancer Chemother Pharmacol 2017; 80: 371–375.
16. Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance or advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother Pharmacol 2018; 82: 655–660.
17. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 377: 523–533.
18. Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 2017; 81: 772–781.
19. Magge RS and DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev 2015; 29: 93–100.
20. Velasco R and Bruna J. Taxane-induced neuropathy. Toxics 2015; 3: 152–169.
21. Gilabert M, Raoul JL, and Rousseau F. How to treat pancreatic adenocarcinoma in elderly: how far can we go in 2017? J Geriatr Oncol 2017; 8: 407–412.
22. Macarulla T, Carrato A, Diaz R, et al. Management and supportive treatment of frail patients with metastatic pancreatic cancer. J Geriatr Oncol 2019; 10: 398–404.
23. Waddell N, Pajic M, Patch AM, et al. Whole genome redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495–501.
24. Connor A, Denroche RE, Jang GH, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol 2017; 3: 774–783.
25. Singh AD, Koay EJ, Chari ST, et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 2019; 156: 2024–2040.
26. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. Epub ahead of print 23 July 2018. DOI: 10.1200/PO.17.00286.
27. De Mestier L, Danset JB, Neuville and et al. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocr Relat Cancer 2016; 23: T57–T67.
28. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 2015; 33: 3124–3129.
29. Murai T, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. JCO Precis Oncol 2012; 72: 5588–5599.
30. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–250.
31. Golan T, Kindler H, Park J, et al. Geographic and ethnic heterogeneity in the BRCA1 or BRCA2 mutation among patients with metastatic pancreatic cancer screened for entry into the POLO trial. J Clin Oncol 2020; 38: 1442–1454.
32. Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol 2019; 30: 1959–1968.
33. Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019; 30: 1437–1447.
34. Park PH, Yamamoto TM, Li H, et al. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Mol Cancer Ther 2020; 19: 602–613.
35. O’Reilly EM, Lee JW, Kazal M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020; 38: 1378–1388.
36. Binder AR, Mick R, O’Hara M, et al. A phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Cancer Res 2019; 79(Suppl. 13): CT234.
37. Hiimi M, Bartholin L and Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J Gastroenterol 2018; 24: 2137–2151.
38. Mota Reyes C, Teller S, Muckenhuber A, et al. Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells. Clin Cancer Res 2020; 26: 220–231.
39. Murakami T, Homma Y, Matsuyama R, et al. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression. J Surg Oncol 2017; 116: 416–426.
40. Turpin A, Chevalier H and Neuzillet C. Maintenance strategies for advanced pancreatic cancer: rationale and issues. Bull Cancer 2018; 105: 739–741.
41. Zhu Y, Zhang H, Chen N, et al. Diagnostic value of various liquid biopsy methods for pancreatic cancer: a systematic review and meta-analysis. Medicine 2020; 99: e18581.
42. Sugimori M, Sugimori K, Tsuchiya H, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci 2020; 111: 266–278.
43. Rofe E, Vivaldi C, Del Re M, et al. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Pharmacogenomics 2019; 20: 49–68.
44. Singh RR and O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs 2020; 80: 647–669.